BCL2 and hepatocellular carcinoma: At high doses (>100 μM), isorhamnetin elevates intracellular ROS levels in Hep3B HCC cells, disrupting mitochondrial metabolism, increasing the Bax/Bcl-2 ratio, and releasing cytochrome c, leading to G2/M cell cycle arrest.